Slaughter and May advised Amyris, Inc on its collaboration with Yifan Pharmaceutical

Slaughter and May advised Amyris, Inc. (Amyris) on its collaboration arrangements with a subsidiary of Yifan Pharmaceutical Co., Ltd. (Yifan). The collaboration was announced on 27 September 2018.

Amyris is an integrated renewable products company and a leader in the development and production of sustainable ingredients, delivering products and services across a number of markets, including specialty and performance chemicals, flavours and fragrances, cosmetics ingredients, pharmaceuticals, and nutraceuticals. Yifan is one of the leading Chinese pharmaceutical companies covering innovation, R&D and manufacturing with a focus on active pharmaceutical ingredients, including nutritional products, biologics, small molecule drugs, and traditional Chinese medicine.

The collaboration is expected to be the start of a long-term relationship between Amyris and Yifan starting with the first target in nutrition for a key molecule to be developed, scaled and manufactured by Amyris.

Slaughter and May supported Amyris’ general counsel, Nicole Kelsey.

Chris McGaffin Partner
Ben Heron Partner
Victoria Lang Associate
David Ives Partner
Michaela Peck Associate